Dow Jones
39.545,96 +114,45 (+0,29%) Nasdaq
16.498,49 +110,25 (+0,67%) Nikkei 225
38.356,06 +176,60 (+0,46%) EUR/USD
1,0823 +0,0029 (+0,27%) Bitcoin EUR
56.716,80 -1.235,34 (-2,13%) CMC Crypto 200
1.262,26 -29,13 (-2,26%)
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
| Chiusura precedente | 1,7000 |
| Aperto | 1,6900 |
| Denaro | 1,7000 x 100 |
| Lettera | 1,7700 x 100 |
| Min-Max giorno | 1,6400 - 1,7400 |
| Intervallo di 52 settimane | 1,6400 - 8,3000 |
| Volume | |
| Media Volume | 274.337 |
| Capitalizzazione | 48,16M |
| Beta (5 anni mensile) | 0,05 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,6500 |
| Prossima data utili | 12 ago 2024 - 16 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,50 |
GlobeNewswireReviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Topline data for RECOVER trial on track for October 2023CUPERTINO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophre
- GlobeNewswire
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will both present and participate in a conference panel at the H.C. Wainwright 25th Annual G
- GlobeNewswire
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - CUPERTINO, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervou
